HomeGermanyAkribion Therapeutics Raises €8M in Seed Financing

Akribion Therapeutics Raises €8M in Seed Financing

-

Akribion Therapeutics, a Zwingenberg, Germany-based early-stage biotech company developing a RNA-guided, nuclease-based technology for programmable cell depletion, raised €8M in Seed funding.

The round was led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others.

The company intends to use the funds to accelerate the development of novel therapeutics based on it proprietary G-dase® E nucleases.

Led by Dr. Michael Krohn and Lukas Linnig, co-Founders and co-CEOs, Akribion is developing RNA-guided, nuclease-based technology for programmable cell depletion. Equipped with a G-dase® E payload, it has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence. This ensures that only the targeted cells are affected, leaving healthy cells unharmed.

Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), the company is exploring applications in additional oncology indications, as well as in autoimmune diseases, fibrosis, infectious diseases, and more.

Akribion was spun out of BRAIN Biotech AG, the specialist in biosolutions for industrial applications.

FinSMEs

04/02/2025

THE DAILY NEWSLETTER - SIGNUP